Mepolizumab
Other Systemic Drugs For Obstructive Airway Diseases
Sold as Bosatria · NUCALA
- Drug class
- Other Systemic Drugs For Obstructive Airway Diseases
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 3
- Products on record
- 9
Overview
Mepolizumab is an active pharmaceutical ingredient in the Other Systemic Drugs For Obstructive Airway Diseases group (R03DX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 5 | February 20, 2026 |
| CA Canada | Health Canada | 3 | March 22, 2025 |
| EU European Union | EMA | 1 | March 9, 2026 |
GBUnited Kingdom· MHRA
5 products
Uses
1). Chronic rhinosinusitis with nasal polyps (CRSwNP) Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.
Chronic obstructive pulmonary disease (COPD) Nucala is indicated as add-on maintenance treatment of adult patients with uncontrolled COPD of an eosinophilic phenotype on a combination of an inhaled corticosteroid (ICS), a long acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA).
1). Eosinophilic granulomatosis with polyangiitis (EGPA) Nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA). 1).
CACanada· Health Canada
3 products
Uses
1 Pregnant Women 11/2023 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES .........................................................................................
2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................................
4 1 INDICATIONS ...................................................................................................................... 1 Pediatrics ..................................................................................................................................
2 Geriatrics .................................................................................................................................. 5 2 CONTRAINDICATIONS ..........................................................................................................
EUEuropean Union· EMA
1 product
Uses
1). 3 Chronic rhinosinusitis with nasal polyps (CRSwNP) Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
1). Eosinophilic granulomatosis with polyangiitis (EGPA) Nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA). 1).
How to take
Sources & citations
- [1]MHRA (UK) · PLGB194940285 · revised January 2, 2026
- [2]Health Canada (DPD) · 02492989 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/003860 · revised March 9, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.